The Genetic Network of Arteriopathy (GENOA) study, begun in 1995, follows a wellcharacterized cohort of hypertensive individuals and their siblings recruited from Jackson, Mississippi (African Americans only) and Rochester, Minnesota (white individuals only; both sites: n=3,437 individuals; 66% female, 57% African Americans, 28-91 years of age).
Readings identified by this program and judged to be invalid by 1 of the investigators were excluded from further analyses.
Brain MRI assessment
All MRI scans were performed on identically equipped Signa 1.5-T MRI scanners (GE Healthcare), and images were centrally processed at the Mayo Clinic. Symmetrical head positioning with respect to orthogonal axes was verified by a series of short scout scans.
Total intracranial volume (head size) was measured from T1-weighted spin-echo sagittal images, each set consisting of 32 contiguous 5-mm thick slices with no interslice gap, field of view=24 cm, and matrix=256×192, obtained with the following sequence: scan time=2.5 minutes, echo time=14 ms, repetitions=2, and replication time=500 ms.22 Total brain and white-matter lesion volumes (cm3) were determined from axial fluid-attenuated inversion recovery images, each set consisting of 48 contiguous 3-mm interleaved slices with no interslice gap, field of view=22 cm, and matrix=256×160, obtained with the following sequence: scan time=9 minutes, echo time=144.8 ms, inversion time=2600 ms, repetition time=11 s, bandwidth=±15.6 kHz, and 1 signal average. Interactive imaging processing steps were performed by a trained image analyst who had no knowledge of the subjects' personal or medical histories or biological relationships. A fully automated algorithm was used to segment each slice of the edited multislice fluid-attenuated inversion recovery sequence into voxels assigned to 1 of the 3 categories: brain, cerebrospinal fluid, or white-matter lesion. The mean absolute error of this method was 1.4% for brain volume and 6.6% for white-matter lesion volume, and the mean test-retest coefficient of variation was 0.3% for brain volume and 1.4% for white-matter lesion volume. 23 The difference between total intracranial volume and brain volume provided a measure of brain atrophy. White-matter hyperintensities in the corona radiata and periventricular zone, as well as infarcts in the central gray matter, were included in the global white-matter lesion volume measurements. Brain scans with cortical infarctions were excluded from the analyses because of the distortion of the white-matter lesion volume estimates that would be introduced into the automated segmentation algorithm.
Other covariates
At the study visit, blood was drawn after an overnight fast of ≥8 hours. Serum creatinine, glucose, and total cholesterol were measured by standard enzymatic methods. were multiplied by −1 for analyses so that higher numbers represented better performance.
The Stroop test involved 3 trials. In the WORD trial, the subject read words of color names printed in black ink. In the COLOR trial, the subject identified colors. Finally, in the COLOR-WORD response inhibition trial, the subject named the color in which a word was presented while ignoring the printed word. Scoring for each trial type is based on the number of correct responses in 45 s. The sum of the 3 trials was used as the final score.
Higher scores indicate better cognitive performance.
(3) Memory
The Rey Auditory Verbal Learning Test (range 0-15) assesses learning and memory using multiple learning trials and a 30-minute delayed recall of 15 items on a list.
(4) Executive Function
The Trail Making Test Part B was used to assess attention, sequencing, mental flexibility, visual search and motor function using time and error counts. 8 A greater time to completion (in seconds) indicated worse performance. Times were multiplied by −1 so that higher scores represented better function. 
